Massachusetts Financial Services Co. MA Sells 17,885,662 Shares of Pfizer Inc. $PFE

Massachusetts Financial Services Co. MA lessened its stake in Pfizer Inc. (NYSE:PFE) by 23.7% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 57,588,660 shares of the biopharmaceutical company’s stock after selling 17,885,662 shares during the period. Massachusetts Financial Services Co. MA’s holdings in Pfizer were worth $1,467,359,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. Norges Bank acquired a new position in shares of Pfizer in the second quarter valued at $2,270,157,000. Vanguard Group Inc. raised its stake in shares of Pfizer by 1.9% in the 2nd quarter. Vanguard Group Inc. now owns 533,363,457 shares of the biopharmaceutical company’s stock valued at $12,928,730,000 after buying an additional 10,198,330 shares in the last quarter. Arrowstreet Capital Limited Partnership raised its stake in shares of Pfizer by 43.4% in the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 18,718,955 shares of the biopharmaceutical company’s stock valued at $453,747,000 after buying an additional 5,662,309 shares in the last quarter. Assenagon Asset Management S.A. lifted its holdings in shares of Pfizer by 75.0% during the 3rd quarter. Assenagon Asset Management S.A. now owns 8,689,103 shares of the biopharmaceutical company’s stock worth $221,398,000 after acquiring an additional 3,722,531 shares during the period. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. boosted its position in shares of Pfizer by 84.9% during the 2nd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 7,561,946 shares of the biopharmaceutical company’s stock valued at $183,302,000 after acquiring an additional 3,472,240 shares in the last quarter. Institutional investors own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on PFE shares. Bank of America dropped their price target on shares of Pfizer from $29.00 to $28.00 and set a “neutral” rating for the company in a research report on Monday, December 15th. Cowen reissued a “hold” rating on shares of Pfizer in a report on Tuesday, December 30th. Guggenheim restated a “buy” rating on shares of Pfizer in a research report on Wednesday, December 17th. UBS Group initiated coverage on Pfizer in a research report on Tuesday, January 6th. They issued a “neutral” rating and a $25.00 price target on the stock. Finally, HSBC restated a “buy” rating and issued a $29.00 target price on shares of Pfizer in a research note on Wednesday, December 10th. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, thirteen have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $27.88.

Pfizer Stock Performance

Shares of NYSE:PFE opened at $25.68 on Friday. The business has a fifty day moving average of $25.35 and a 200-day moving average of $24.99. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.97 and a current ratio of 1.28. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $27.69. The firm has a market cap of $146.01 billion, a PE ratio of 14.93 and a beta of 0.47.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.79 by $0.08. Pfizer had a return on equity of 20.17% and a net margin of 15.65%.The business had revenue of $16.65 billion during the quarter, compared to analysts’ expectations of $16.94 billion. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. On average, equities research analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, January 23rd will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.7%. The ex-dividend date is Friday, January 23rd. Pfizer’s dividend payout ratio is presently 100.00%.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.